Several hemophilia A or B treatments are in development or have been approved since 2021. Among these are the “rebalancing” preparations that suppress control proteins such as tissue factor pathway inhibitor (TFPI), antithrombin (AT), or activated protein C (APC). Rebalancing preparations are designed to compensate for the bleeding tendencies in FVIII or FIX deficiency without using factor bypassing agents or factor replacement concentrates. Our August question asks you to identify the preparation that’s an RNA inhibitor (RNAi) that suppresses antithrombin mRNA production.
Jul 30 2024
Comments (0)
Bleeding Disorders
No comments here.